| Vol. 12.42 – 6 November, 2020 |
| |
|
|
| Scientists demonstrated a general strategy to fabricate personalized nanovaccines based on a cationic fluoropolymer for post-surgical cancer immunotherapy. [Nature Nanotechnology] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators developed a bone marrow-avid nanobiologic platform designed specifically to induce trained immunity. They established the potent anti-tumor capabilities of our lead candidate MTP 10-HDL in a B16F10 mouse melanoma model. [Cell] |
|
|
|
| Researchers combined lineage tracing with antibody cloning from single B cells to examine the role of affinity in B cell selection into germinal centers and the memory B cell compartment in mice immunized with an HIV-1 antigen. [Cell] |
|
|
|
| Scientists found that Netrin G1 (NetG1)+ cancer-associated fibroblasts (CAFs) support pancreatic ductal adenocarcinoma survival, through a NetG1 mediated effect on glutamate/glutamine metabolism. NetG1+ CAFs were intrinsically immunosuppressive and inhibited NK cell mediated killing of tumor cells. [Cancer Discovery] |
|
|
|
| Investigators uncovered rare effector-phase CD8+ T cells expressing high amounts of the transcription factor Tcf7 that showed no evidence of prior cytolytic differentiation. [Immunity] |
|
|
|
| The authors showed that miR‐7 deficiency led to exacerbated pathology in ConA‐induced murine acute autoimmune liver injury model, accompanied with hyperactivation state of CD4+ T cells. [Hepatology] |
|
|
|
| Scientists showed that necrosis in glioblastoma (GBM) involves neutrophil-triggered ferroptosis. In a hyperactivated transcriptional coactivator with PDZ-binding motif-driven GBM mouse model, neutrophils coincide with necrosis temporally and spatially. [Nature Communications] |
|
|
|
| Investigators showed that beclin 2 functioned as a negative regulator in innate immune signaling and tumor development through non-canonical autophagy. [Autophagy] |
|
|
|
| Researchers describe a CRISPR/Cas9–based platform that used primary mouse T cells and permitted establishment of the composition of their LAT, CD5, and CD6 signalosomes in only four months. [Journal of Experimental Medicine] |
|
|
|
| Scientist report that persistent activation of signal transducer and activator of transcription 5 in tumor-specific CD4+ T cells drove the development of polyfunctional T cells. [Science Immunology] |
|
|
|
|
| Scientists look into the advancements in microfluidic technologies applied to research on immune checkpoint blockade treatment and its potential shift from proof-of-principle stage to clinical application. [Cancer Gene Therapy] |
|
|
|
|
| Pfizer Inc. announced that the FDA accepted for filing and granted Priority Review designation to the company’s New Drug Application for abrocitini, an investigational oral once-daily Janus kinase 1 inhibitor, for the treatment of moderate to severe atopic dermatitis in patients 12 and older. [Pfizer Inc. (BusinessWire, Inc.)] |
|
|
|
| Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB announced a strategic collaboration to accelerate the advancement of systemic pegcetacoplan, a targeted C3 therapy, for the treatment of multiple rare diseases with high unmet need that impact more than 275,000 patients globally. [Apellis Pharmaceuticals, Inc.] |
|
|
|
|
| March 22 – March 24, 2021 Virtual |
|
|
|
|
|
| Genentech, Inc. – South San Francisco, California, United States |
|
|
|
| Queen’s University – Kingston, Ontario, Canada |
|
|
|
| H. Lee Moffitt Cancer Center & Research Institute – Tampa, Florida, United States |
|
|
|
| Terasaki Research Institute – Los Angeles, California, United States |
|
|
|
| Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
|